Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
505 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Relapsed Multiple Myeloma - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Relapsed Multiple Myeloma - Pipeline Review, H2 2015', provides an overview of the Relapsed Multiple Myeloma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsed Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsed Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsed Multiple Myeloma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsed Multiple Myeloma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Relapsed Multiple Myeloma Overview 10 Therapeutics Development 11 Pipeline Products for Relapsed Multiple Myeloma - Overview 11 Pipeline Products for Relapsed Multiple Myeloma - Comparative Analysis 12 Relapsed Multiple Myeloma - Therapeutics under Development by Companies 13 Relapsed Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes 18 Relapsed Multiple Myeloma - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Relapsed Multiple Myeloma - Products under Development by Companies 22 Relapsed Multiple Myeloma - Products under Investigation by Universities/Institutes 28 Relapsed Multiple Myeloma - Companies Involved in Therapeutics Development 29 4SC AG 29 AB Science SA 30 AbbVie Inc. 31 Acetylon Pharmaceuticals, Inc. 32 Altor BioScience Corporation 33 Amgen Inc. 34 Arno Therapeutics, Inc. 35 Array BioPharma Inc. 36 Astellas Pharma Inc. 37 Astex Pharmaceuticals, Inc. 38 Atara Biotherapeutics, Inc. 39 Biotest AG 40 Boehringer Ingelheim GmbH 41 Bristol-Myers Squibb Company 42 Calithera Biosciences, Inc. 43 Celgene Corporation 44 Cellectar Biosciences, Inc. 45 Cleave Biosciences 46 Curis, Inc. 47 Daiichi Sankyo Company, Limited 48 Exelixis, Inc. 49 F. Hoffmann-La Roche Ltd. 50 GlaxoSmithKline Plc 51 IGF Oncology, LLC. 52 Immunomedics, Inc. 53 Jasco Pharmaceuticals, LLC. 54 Johnson & Johnson 55 JW Pharmaceutical Corporation 56 Karyopharm Therapeutics, Inc. 57 MedImmune, LLC 58 Medivation, Inc. 59 Merck & Co., Inc. 60 Millennium Pharmaceuticals, Inc. 61 MorphoSys AG 62 Novartis AG 63 Noxxon Pharma AG 64 Oncolytics Biotech Inc. 65 Oncopeptides AB 66 Onyx Pharmaceuticals, Inc. 67 Patrys Limited 68 Pfizer Inc. 69 Pharma Mar, S.A. 70 Sanofi 71 Stemline Therapeutics, Inc. 72 Sumitomo Dainippon Pharma Co., Ltd. 73 Synta Pharmaceuticals Corp. 74 Threshold Pharmaceuticals, Inc. 75 Vivolux AB 76 Relapsed Multiple Myeloma - Therapeutics Assessment 77 Assessment by Monotherapy Products 77 Assessment by Combination Products 78 Assessment by Target 79 Assessment by Mechanism of Action 85 Assessment by Route of Administration 90 Assessment by Molecule Type 92 Drug Profiles 94 4SC-202 - Drug Profile 94 765IGF-MTX - Drug Profile 96 ABBV-838 - Drug Profile 97 acalabrutinib - Drug Profile 98 ACY-241 - Drug Profile 101 afuresertib hydrochloride - Drug Profile 103 alisertib - Drug Profile 106 alpelisib - Drug Profile 110 ALT-801 - Drug Profile 112 ALT-803 - Drug Profile 115 AMG-224 - Drug Profile 118 amrubicin hydrochloride - Drug Profile 119 AR-42 - Drug Profile 121 AT-7519 - Drug Profile 123 AT-9283 - Drug Profile 126 B-701 - Drug Profile 128 bendamustine hydrochloride - Drug Profile 129 BI-836909 - Drug Profile 132 BMS-986016 - Drug Profile 133 cabozantinib s-malate - Drug Profile 134 carfilzomib - Drug Profile 138 CB-5083 - Drug Profile 142 CB-839 - Drug Profile 143 CC-90002 - Drug Profile 145 Cell Therapy to Target WT1 for Cancer - Drug Profile 146 Cellular Immunotherapy to Target B-Cell Maturation Factor for Multiple Myeloma - Drug Profile 147 Cellular Immunotherapy to Target CD138 for Relapsed and Refractory Multiple Myeloma - Drug Profile 148 CUDC-907 - Drug Profile 149 CWP-291 - Drug Profile 151 daratumumab - Drug Profile 153 DKN-01 - Drug Profile 157 DS-3032 - Drug Profile 159 elotuzumab - Drug Profile 160 erismodegib - Drug Profile 162 evofosfamide - Drug Profile 165 filanesib - Drug Profile 173 ganetespib - Drug Profile 175 GSK-2857916 - Drug Profile 180 GSK-525762 - Drug Profile 181 I131-CLR1404 - Drug Profile 182 ibrutinib - Drug Profile 184 indatuximab ravtansine - Drug Profile 191 inebilizumab - Drug Profile 193 ipilimumab - Drug Profile 195 isatuximab - Drug Profile 200 ixazomib citrate - Drug Profile 202 JP-11646 - Drug Profile 206 LCL-161 - Drug Profile 207 lirilumab - Drug Profile 209 marizomib - Drug Profile 211 masitinib - Drug Profile 213 Melflufen - Drug Profile 218 milatuzumab - Drug Profile 220 MOR-202 - Drug Profile 222 MV-NIS - Drug Profile 224 NL-101 - Drug Profile 226 olaptesed pegol - Drug Profile 227 oprozomib - Drug Profile 230 palbociclib - Drug Profile 232 PATSM-6 - Drug Profile 236 pelareorep - Drug Profile 238 pembrolizumab - Drug Profile 243 pidilizumab - Drug Profile 252 PIM-447 - Drug Profile 254 plerixafor - Drug Profile 255 plitidepsin - Drug Profile 257 quisinostat hydrochloride - Drug Profile 259 Recombinant Protein for Oncology - Drug Profile 261 ricolinostat - Drug Profile 263 RRX-001 - Drug Profile 265 selinexor - Drug Profile 267 SL-401 - Drug Profile 273 trametinib dimethyl sulfoxide + uprosertib - Drug Profile 275 ulocuplumab - Drug Profile 277 urelumab - Drug Profile 279 vemurafenib - Drug Profile 281 venetoclax - Drug Profile 285 VLX-1570 - Drug Profile 288 vorinostat - Drug Profile 290 Relapsed Multiple Myeloma - Recent Pipeline Updates 294 Relapsed Multiple Myeloma - Dormant Projects 483 Relapsed Multiple Myeloma - Discontinued Products 487 Relapsed Multiple Myeloma - Product Development Milestones 488 Featured News & Press Releases 488 Appendix 498 Methodology 498 Coverage 498 Secondary Research 498 Primary Research 498 Expert Panel Validation 498 Contact Us 498 Disclaimer 499
List of Tables
Number of Products under Development for Relapsed Multiple Myeloma, H2 2015 17 Number of Products under Development for Relapsed Multiple Myeloma - Comparative Analysis, H2 2015 18 Number of Products under Development by Companies, H2 2015 20 Number of Products under Development by Companies, H2 2015 (Contd..1) 21 Number of Products under Development by Companies, H2 2015 (Contd..2) 22 Number of Products under Development by Companies, H2 2015 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H2 2015 24 Comparative Analysis by Late Stage Development, H2 2015 25 Comparative Analysis by Clinical Stage Development, H2 2015 26 Comparative Analysis by Early Stage Development, H2 2015 27 Products under Development by Companies, H2 2015 28 Products under Development by Companies, H2 2015 (Contd..1) 29 Products under Development by Companies, H2 2015 (Contd..2) 30 Products under Development by Companies, H2 2015 (Contd..3) 31 Products under Development by Companies, H2 2015 (Contd..4) 32 Products under Development by Companies, H2 2015 (Contd..5) 33 Products under Investigation by Universities/Institutes, H2 2015 34 Relapsed Multiple Myeloma - Pipeline by 4SC AG, H2 2015 35 Relapsed Multiple Myeloma - Pipeline by AB Science SA, H2 2015 36 Relapsed Multiple Myeloma - Pipeline by AbbVie Inc., H2 2015 37 Relapsed Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 38 Relapsed Multiple Myeloma - Pipeline by Altor BioScience Corporation, H2 2015 39 Relapsed Multiple Myeloma - Pipeline by Amgen Inc., H2 2015 40 Relapsed Multiple Myeloma - Pipeline by Arno Therapeutics, Inc., H2 2015 41 Relapsed Multiple Myeloma - Pipeline by Array BioPharma Inc., H2 2015 42 Relapsed Multiple Myeloma - Pipeline by Astellas Pharma Inc., H2 2015 43 Relapsed Multiple Myeloma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 44 Relapsed Multiple Myeloma - Pipeline by Atara Biotherapeutics, Inc., H2 2015 45 Relapsed Multiple Myeloma - Pipeline by Biotest AG, H2 2015 46 Relapsed Multiple Myeloma - Pipeline by Boehringer Ingelheim GmbH, H2 2015 47 Relapsed Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H2 2015 48 Relapsed Multiple Myeloma - Pipeline by Calithera Biosciences, Inc., H2 2015 49 Relapsed Multiple Myeloma - Pipeline by Celgene Corporation, H2 2015 50 Relapsed Multiple Myeloma - Pipeline by Cellectar Biosciences, Inc., H2 2015 51 Relapsed Multiple Myeloma - Pipeline by Cleave Biosciences, H2 2015 52 Relapsed Multiple Myeloma - Pipeline by Curis, Inc., H2 2015 53 Relapsed Multiple Myeloma - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 54 Relapsed Multiple Myeloma - Pipeline by Exelixis, Inc., H2 2015 55 Relapsed Multiple Myeloma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 56 Relapsed Multiple Myeloma - Pipeline by GlaxoSmithKline Plc, H2 2015 57 Relapsed Multiple Myeloma - Pipeline by IGF Oncology, LLC., H2 2015 58 Relapsed Multiple Myeloma - Pipeline by Immunomedics, Inc., H2 2015 59 Relapsed Multiple Myeloma - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015 60 Relapsed Multiple Myeloma - Pipeline by Johnson & Johnson, H2 2015 61 Relapsed Multiple Myeloma - Pipeline by JW Pharmaceutical Corporation, H2 2015 62 Relapsed Multiple Myeloma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 63 Relapsed Multiple Myeloma - Pipeline by MedImmune, LLC, H2 2015 64 Relapsed Multiple Myeloma - Pipeline by Medivation, Inc., H2 2015 65 Relapsed Multiple Myeloma - Pipeline by Merck & Co., Inc., H2 2015 66 Relapsed Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 67 Relapsed Multiple Myeloma - Pipeline by MorphoSys AG, H2 2015 68 Relapsed Multiple Myeloma - Pipeline by Novartis AG, H2 2015 69 Relapsed Multiple Myeloma - Pipeline by Noxxon Pharma AG, H2 2015 70 Relapsed Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H2 2015 71 Relapsed Multiple Myeloma - Pipeline by Oncopeptides AB, H2 2015 72 Relapsed Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 73 Relapsed Multiple Myeloma - Pipeline by Patrys Limited, H2 2015 74 Relapsed Multiple Myeloma - Pipeline by Pfizer Inc., H2 2015 75 Relapsed Multiple Myeloma - Pipeline by Pharma Mar, S.A., H2 2015 76 Relapsed Multiple Myeloma - Pipeline by Sanofi, H2 2015 77 Relapsed Multiple Myeloma - Pipeline by Stemline Therapeutics, Inc., H2 2015 78 Relapsed Multiple Myeloma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 79 Relapsed Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H2 2015 80 Relapsed Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 81 Relapsed Multiple Myeloma - Pipeline by Vivolux AB, H2 2015 82 Assessment by Monotherapy Products, H2 2015 83 Assessment by Combination Products, H2 2015 84 Number of Products by Stage and Target, H2 2015 86 Number of Products by Stage and Mechanism of Action, H2 2015 92 Number of Products by Stage and Route of Administration, H2 2015 97 Number of Products by Stage and Molecule Type, H2 2015 99 Relapsed Multiple Myeloma Therapeutics - Recent Pipeline Updates, H2 2015 300 Relapsed Multiple Myeloma - Dormant Projects, H2 2015 489 Relapsed Multiple Myeloma - Dormant Projects (Contd..1), H2 2015 490 Relapsed Multiple Myeloma - Dormant Projects (Contd..2), H2 2015 491 Relapsed Multiple Myeloma - Dormant Projects (Contd..3), H2 2015 492 Relapsed Multiple Myeloma - Discontinued Products, H2 2015 493
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
